Biosynth Acquires celares to Expand Bioconjugation and Polymer Drug Delivery Capabilities
July 11, 2023
Biosynth, a Switzerland-based supplier of critical raw materials and manufacturing services, acquired Berlin-based celares, a developer and manufacturer of bioconjugates, activated PEGs and polymer-based drug delivery excipients. The acquisition strengthens Biosynth's capabilities in conjugate vaccines and bioconjugate drugs and adds GMP bioconjugation and PEGylation manufacturing in Berlin to its service offering.
- Buyers
- Biosynth
- Targets
- celares GmbH
- Industry
- Biotechnology
- Location
- Berlin, Germany
- Transaction Type
- Buyout
Explore More
Build a buyer list for your deal
Find active buyers from recent acquisition patterns and move straight into outreach.